|
Market Closed -
London S.E.
16:35:01 30/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 0.1050 GBX | -.--% |
|
+5.00% | -58.82% |
| 10-22 | WINNERS & LOSERS: Camellia slumps on macadamia woe; Record climbs | AN |
| 10-20 | WINNERS & LOSERS: Ixico beats expectations; Shearwater wins deal | AN |
| Market Cap | 3.78M 5.07M 4.54M 4.18M 7.07M 481M 7.21M 49.8M 19.99M 253M 19.03M 18.62M 799M | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 3.69M 4.94M 4.42M 4.07M 6.89M 469M 7.02M 48.52M 19.48M 247M 18.54M 18.14M 778M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| LVRT | Delayed | |
Börse Stuttgart
| 1RT | Delayed | |
|
Deutsche Boerse AG
| 1RT | Delayed |
| 23/05/25 | Nuformix : Prospectus | PU |
| 05/10/23 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 20/12/22 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 20/12/22 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 18/02/20 | Nuformix : Appointment of Dr Karl Keegan | PU |
| 1 week | +5.00% | ||
| 1 month | -27.59% | ||
| 3 months | -27.59% | ||
| 6 months | -38.24% | ||
| Current year | -58.82% |
| 1 week | 0.09 |  | 0.11 |
| 1 month | 0.09 | | 0.14 |
| Current year | 0.09 | | 0.4 |
| 1 year | 0.09 | | 0.56 |
| 3 years | 0.04 | | 0.56 |
| 5 years | 0.04 | | 1.93 |
| 10 years | 0.04 | | 14.89 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 28/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Gooding
BRD | Director/Board Member | 53 | 30/06/2022 |
| Director/Board Member | 61 | 01/12/2020 | |
Timothy Metcalfe
CHM | Chairman | 54 | 31/08/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 05/11/24 | Free | Director | 22,000,000 | 2.6852% | ||
| 05/11/24 | Free | Chairman | 22,000,000 | 2.6852% | ||
| 05/11/24 | Free | Founder | 12,000,000 | 1.4646% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +5.00% | -72.37% | -62.50% | 3.67M | |
| +3.19% | +11.31% | +64.28% | +155.91% | 1,263B | |
| -0.73% | +3.56% | +44.65% | +84.17% | 658B | |
| +1.41% | +3.24% | +35.25% | +108.88% | 521B | |
| +0.42% | +3.20% | +55.81% | +72.50% | 391B | |
| +2.18% | +2.93% | +73.90% | +45.59% | 369B | |
| +1.12% | +4.52% | +34.76% | +58.24% | 307B | |
| +6.96% | +8.86% | +11.95% | +36.20% | 290B | |
| +1.15% | +6.09% | +56.15% | +82.25% | 252B | |
| +3.06% | +9.38% | +42.48% | +117.32% | 212B | |
| Average | +1.88% | +5.81% | +34.69% | +69.85% | 426.19B | |
| Weighted average by Cap. | +2.01% | +6.60% | +50.51% | +100.44% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.64M -4.88M -4.37M -4.02M -6.81M -463M -6.93M -47.93M -19.24M -244M -18.31M -17.92M -768M | -653K -874K -783K -720K -1.22M -83.01M -1.24M -8.59M -3.45M -43.67M -3.28M -3.21M -138M |
| Net Debt | -20.21K -27.08K -24.25K -22.3K -37.78K -2.57M -38.48K -266K -107K -1.35M -102K -99.45K -4.26M | -97.55K -131K -117K -108K -182K -12.41M -186K -1.28M -515K -6.53M -490K -480K -20.59M |
Employees
3
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | GBX 0.1050 | -.--% | 3,668,015 |
| 29/10/26 | GBX 0.1050 | -.--% | 7,780,430 |
| 28/10/26 | GBX 0.1050 | -.--% | 7,162,872 |
| 27/10/26 | GBX 0.1050 | +5.00% | 10,503,180 |
| 26/10/26 | GBX 0.1000 | -.--% | 51,541,206 |
- Stock Market
- Stocks
- LVRT Stock
Select your edition
All financial news and data tailored to specific country editions
